NASDAQ: SILO · Life Sciences · 4 alerts · CIK 1514183
Share price
$1.58Close, Nov 16
Market cap
$3.4M
Shares outstanding
2.16MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Silo Pharma, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, Silo Pharma reported a net loss of $2.84 million, an improvement from the $3.35 million loss in the prior year period. The company's cash position increased to $6.09 million, bolstered by a $0.70 million gain from the termination of a sublicense agreement and financing activities.
Silo Pharma entered into securities purchase agreements with accredited investors for a private placement of 136,005 common shares and 430,661 pre-funded warrants. The offering is expected to generate approximately $815,000 in net proceeds for working capital and general corporate purposes. The company also agreed to file a registration statement for the resale of the securities within 30 days of the agreement.
Silo Pharma, Inc. entered into an asset purchase agreement with Larry King to acquire certain software and related intellectual property. In consideration for the assets, the company issued 150,000 shares of its common stock, which are subject to a 12-month lock-up period.
Silo Pharma M&A Deal with Norsight Consulting Inc.
Silo Pharma, Inc. entered into an asset purchase agreement to acquire software, technology, and related intellectual property from Norsight Consulting Inc. In consideration for the assets, Silo Pharma issued a warrant to Norsight to purchase up to 300,000 shares of common stock at an exercise price of $1.51 per share. The acquired assets include trademarks, domain names, data, and trade secrets related to the purchased technology.